FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

著者: Uğur Şahin, Ö. Türeci, Georgy M. Manikhas, Florian Lordick, Andriy Rusyn, Ihor Vynnychenko, Assen Dudov, I. Bazin, Igor Bondarenko, Bohuslav Melichar, Karl Dhaene, Kai Wiechen, Christoph Huber, Daniel Maurus, Ahsan M. Arozullah, J.W. Park, Martin Schüler, S. Al-Batran - Annals of Oncology 2021 被引用: 359